381 Millennium - Eighteenth Edition SCIENCES, PHARMACEUTICALS AND BIOTECHNOLOGY PRINCIPAL SCIENTIST Stablix Inc. Needham, MA HYDROGEOLOGIST IV Washington State Department of Ecology Seattle, WA BENJAMIN LEVIN, PHD Christopher J. Martin serves as the regional hydrogeologist for the Water Quality Program in northwest Washington. He has worked for the Washington State Department of Ecology since 2012, having previously worked as a hydrogeologist with a United States Department of Energy contractor in Idaho. While attending Stockton University, Mr. Martin became interested in geology and graduated with a BS in the subject in 1981. He later received an MS in hydrogeology from the University of Idaho. His significant career contributions include drafting a state waste discharge permit for a local slaughterhouse, addressing critical wastewater management challenges and providing safeguards against surface water contamination. Additionally, he demonstrated his expertise in regulatory compliance and environmental protection through his work on permits for industries discharging wastewater into the ground. Moving forward, Mr. Martin is planning for retirement. However, he remains passionate about his work and is considering becoming a global consultant, leveraging his extensive experience to provide advice to businesses and governments. CHRISTOPHER J. MARTIN Dr. Benjaming Levin is a dedicated scientist with a strong background in chemistry and drug discovery. He began his academic journey with a BS in chemistry from the University of Rochester and earned a PhD in chemistry at Boston University. Transitioning from fundamental research to applied science, his postdoctoral work emphasized creating impactful, practical solutions for new medication development. With a robust career spanning various senior roles, Dr. Levin contributed significantly as a senior scientist at Dewpoint Therapeutics and Stablix Inc., where he later became a principal scientist in Boston. His expertise covers early-stage drug discovery, from target validation to the development of therapeutic small molecules. Known for bridging enzymology with cell biology, he has led key initiatives in highthroughput screening and molecular characterization. Beyond his industry roles, Dr. Levin has contributed to scholarly literature and has published in journals such as the Journal of Biological Inorganic Chemistry. Currently the founder of iO2 Therapeutics, he is leading efforts to leverage tumor microenvironment dynamics for innovative cancer treatments. He remains committed to advancing scientific research and delivering breakthrough medications for patients.
RkJQdWJsaXNoZXIy MTQ5NDA2